Biocryst Pharmaceuticals (BCRX) Announces Positive Results From Opus-1, A Phase 2 Trial Of BCX4161 For The Prophylactic Treatment Of Hereditary Angioedema
5/27/2014 9:03:06 AM
RESEARCH TRIANGLE PARK, N.C., May 27, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced preliminary results from its OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). The trial met the primary efficacy endpoint, several secondary endpoints and all other objectives established for the trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by